Interferon-b (IFN-b) is one of the major drugs for multiple sclerosis (MS) treatment. The purpose of this study was to characterize the transcriptional effects induced by intramuscular IFN-b-1a therapy in patients with relapsingremitting form of MS. By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells of 24 MS patients within the first 4 weeks of IFN-b administration. We identified 121 genes that were significantly up-or downregulated compared with baseline, with stronger changed expression at 1 week after start of therapy. Eleven transcription factor-binding sites (TFBS) are overrepresented in the regulatory regions of these genes, including those of IFN regulatory factors and NF-kB. We then applied TFBS-integrating least angle regression, a novel integrative algorithm for deriving gene regulatory networks from gene expression data and TFBS information, to reconstruct the underlying network of molecular interactions. An NF-kB-centered sub-network of genes was highly expressed in patients with IFN-b-related side effects. Expression alterations were confirmed by real-time PCR and literature mining was applied to evaluate network inference accuracy.
Introduction
Multiple sclerosis (MS) is an idiopathic inflammatory disorder of the central nervous system and the most common disabling neurologic disease of young adults. It is a lifelong disease that affects the nervous system by destroying the protective covering (myelin) that surrounds nerve fibers, thereby provoking impaired nerve conduction. Genetic susceptibility, environmental exposure and immune dysregulation are thought to have a significant role in its pathogenesis. An autoimmune basis is assumed to cause lesions in the brain and spinal cord, but it is less clear how the autoimmune processes originate and maintain. [1] [2] [3] [4] At present there is no cure for MS, and existing therapies are designed primarily to prevent lesion formation and brain atrophy, decrease the rate and severity of relapses and delay the resulting disability by reducing levels of inflammation. Interferon-b (IFN-b) is currently the most established treatment for controlling the exacerbations in relapsing-remitting MS and several studies have confirmed its clinical benefit. [5] [6] [7] IFN-b is a natural human pleiotropic cytokine with antiproliferative and immunomodulatory activities that is produced by various cell types including fibroblasts and macrophages. It exerts its biological effects by binding to specific cell surface receptors. This binding initiates a cascade of intracellular events, which leads to the activation of transcription factors (TFs) including signal transducers and activators of transcription, IFN regulatory factors and NF-kB. 8 These translocate to the nucleus and drive the expression of numerous genes that could serve as biological markers of IFN-b activity (for example, MX1, TNFSF10, B2M and IFIT1). Transcript levels of these biological response markers rapidly increase within 12 h of IFN-b administration and remain elevated for at least 3 days. [9] [10] [11] [12] Although the initial steps of the intracellular signaling pathways that are triggered by IFN-b have been delineated in great detail, the mechanisms instrumental for its therapeutic efficacy in MS are still poorly understood. It is likely that of the many (immune system) processes that are influenced by IFN-b-directly or indirectly as a consequence of the activity of induced proteins-only a small proportion is responsible for the clinical benefit. This suggests a cascade of events following IFN-b administration, in which some are beneficial, others may have no effect on MS, and still others may be deleterious and cause side effects. The balance of all these effects is favorable in most MS patients and leads to reduced disease activity and lowered accumulation of disease burden. However, clinical trials demonstrated that MS patients exhibit considerable interindividual heterogeneity in their clinical course and response to IFN-b therapy. Approximately onethird of the patients suffer from a higher or identical annual relapse rate while on treatment than before (non-responders). 13 At present, no established markers capable of predicting either favorable or detrimental responses to IFN-b are available.
Different IFN-b medications are available for MS. Three have been approved as first-line therapies for the treatment of relapsing-remitting MS in the mid-1990s: Avonex (IFN-b1a intramuscular (i.m.); Biogen Idec, Cambridge, MA, USA), Rebif (IFN-b-1a subcutaneous; Merck Serono, Darmstadt, Germany) and Betaferon (IFN-b-1b subcutaneous; Bayer Schering, Leverkusen, Germany). i.m. IFN-b-1a is given once a week, whereas subcutaneous (s.c.) IFN-b-1a and IFN-b-1b requires three to four injections per week. IFN-b-1a i.m. appears to be well tolerated with 4% of treated patients discontinuing injections because of adverse events in the pivotal clinical trial. 6 Moreover, it has the lowest incidence (approximately 2%) of neutralizing antibodies. 14 It has been repeatedly demonstrated that IFN-b-mediated gene-regulatory effects can be accessed by expression profiling of peripheral blood cells using DNA microarrays. 15, 16 In the recent past, a few high-throughput analyses have been completed in an attempt to explicitly characterize the global transcriptional changes in the blood that occur in response to IFN-b-1a i.m. (Table 1 ). In a pharmacogenomic study by Weinstock-Guttman et al., B4000 genes were measured, of which about 1500 were identified as up-or downregulated after the first dose and after chronic administration of IFN-b-1a i.m. 11 This showed that the therapy induces changes in the expression of many genes Five microarray studies have been conducted in this field since 2003. The table provides the number of patients examined and the sample material used to measure mRNA levels. Moreover, the blood sampling time points, as well as the number of genes found modulated in expression during therapy (on the basis of different filtering criteria, '#Genes mk') are shown.
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M Hecker et al (for example, cytokines and cell adhesion molecules), and that IFN-b has effects on multiple processes. However, existing studies primarily explored the transient immediate gene expression changes few hours after therapy onset, and to a lesser extent the (possibly indirect) regulatory effects of IFN-b that appear at a late stage between two subsequent injections and sustain for a longer period of time. Moreover, most reports just list differentially expressed genes, but as genes tend to interact, it is more meaningful to arrange them in gene regulatory networks (GRNs) based on expression data and known molecular interactions. A GRN, in principle, denotes the assembly of regulatory effects that conduct the mutual transcriptional control of a set of genes. Various modeling approaches have been proposed to reconstruct GRNs from experimental data on the basis of different mathematical concepts and learning strategies, and distinct degrees of abstraction. Novel network inference algorithms integrate diverse types of data (for example, gene expression data and protein-DNA interaction data), incorporate previous biological knowledge (for example, from scientific literature) and use specific modeling constraints to obtain more accurate GRN models. 21, 22 A network analysis could provide testable hypotheses about the drug's mechanisms of action and may have clinical implications by accentuating gene sub-networks with expression differences between responders and partial responders or patients with and without side effects to the therapy. In 2007, Fernald et al. 20 published the first and only study that incorporated computational network inference to investigate gene regulation in response to IFN-b-1a i.m. They used mutual information as a similarity measure to derive a large network of genes.
Here, we used DNA microarrays to measure the transcriptional profile of peripheral blood mononuclear cells (PBMC) from 24 MS patients within the first month of weekly i.m. injection of IFN-b-1a. The data allowed to assess sustained changes in expression and we analyzed the functional characteristics and transcription factor-binding sites (TFBS) of the genes up-or downregulated during therapy. Using an integrative modeling approach we reconstructed a GRN in which TFs are linked to the modulated genes to provide a deeper molecular understanding of the drug's regulatory mechanisms early in therapy. We further examined whether specific expression patterns relate to flu-like side effects, which are a common cause of early treatment failure. 23 
Materials and methods

Study population
A total of 24 Caucasian patients (18 females/6 males, mean age 35.8 years; Table 2 ) diagnosed with relapsing-remitting 24 were analyzed in this study. The patients were prescribed a first therapy with 30 mg onceweekly, i.m. IFN-b-1a (Avonex; Biogen Idec). None of the patients had previously been medicated with immunomodulatory or immunosuppressive agents or had ever received cytotoxic treatments, and all were free of glucocorticoid treatment for at least 30 days before blood extraction. Patients were assessed neurologically and rated using the expanded disability status scale at regular intervals. The study was approved by the University of Rostock's ethics committee and carried out according to the declaration of Helsinki.
Gene expression analysis using microarrays With informed consent, 15 ml peripheral venous ethylenediaminetetraacetic acid blood samples were taken from all patients immediately before first, second and fifth IFN-b injection, that is, at baseline as well as 1 and 4 weeks post therapy initiation. The samples were always collected at the same time of the day and processed within 1 h. Total RNA of Ficoll-isolated PBMC from each sample was extracted following manufacturer's protocol (RNeasy; Qiagen, Hilden, Germany). We used PBMC instead of whole blood to reduce interferences of globin RNA and thus increase the sensitivity of the microarray hybridization results. Initial RNA and final complementary RNA concentrations were determined spectrophotometrically by a Nanodrop 1000 (Thermo Fisher Scientific, Waltham, MA, USA) and quality control was performed by native ethidium bromide agarose gel electrophoresis. Samples of 7 mg total RNA were labeled and hybridized to Affymetrix (Santa Clara, CA, USA) human genome U133 A and B arrays in accordance with the supplier's instructions. The arrays were scanned at 3-mm resolution using the Hewlett Packard GeneArray Scanner G2500A (Affymetrix). The raw data were stored according to the MIAME standard and are available from Gene Expression Omnibus (accession number GSE19285, http://www.ncbi.nlm.nih.gov/geo/).
Validation of the microarray data by real-time PCR Quantitative real-time reverse transcription PCR was used to confirm changes in gene expression revealed by the DNA microarray experiments. We measured the expression levels of 15 selected genes in a subset of the samples. Details on the experimental procedure, as well as on the analysis of the real-time PCR data are described in Supplementary Materials and Methods.
Microarray data preprocessing
In the applied Affymetrix microarrays most probesets include probes matching transcripts from more than one gene and probes that do not match any transcribed sequence. Therefore, we utilized custom chip definition files that are based on the information contained in the GeneAnnot database version 1.8 25 (http://bioinfo2.weizmann. ac.il/geneannot/). GeneAnnot-based chip definition files are composed of probesets including exclusively probes matching a single gene and thus allow for a more reliable determination of transcript levels. We used version 1.5.0 of the custom chip definition files (for HG-U133 A and B) and the MAS5.0 algorithm to preprocess the raw probe intensities. Data normalization was performed, separately for the arrays of type A and B, by a loess fit to the data with span ¼ 0.05 (using R package affy). Each A-and B-chip yielded mRNA abundances of 11220 and 6771 human genes, respectively. For the 2257 genes that were measured with both chip types, we used the signal intensities of the A-chip.
Filtering differentially expressed genes
To identify genes substantially up-or downregulated within the first month of therapy, we used a combination of two criteria: a test of statistical significance and a fold change variant. First, we analyzed which genes showed significant expression changes by use of a paired t-test comparing the baseline expression levels with the levels at 1 week and 4 weeks into therapy. To further narrow down the filtering result, we evaluated signal intensity-dependent fold changes (MAID filtering) 26 (http://www.hki-jena.de/index.php/0/2/ 490). In this way, we took into account that the variability in the (log) fold changes increases as the measured signal intensity decreases. 27 The absolute value of a gene's MAID score is higher, the more its expression level is altered after start of therapy, and it is generally lower for weaklyexpressed genes. Finally, we selected the protein-coding genes having |MAID score|43.0 and t-test P-valueo0.01 as IFN-b-responsive genes.
To provide an estimate of the number of genes passing the filtering by chance, a permutation test was performed. The data set was permutated 1000 times by randomly rearranging the temporal sequence of the data of each patient. The same filtering criteria as described above were applied to each permutation.
In addition, we analyzed the genes with significant expression changes to identify a subset of genes whose expression correlates with IFN-b-related side effects. For this purpose, we compared the baseline transcript levels of patients with and without flu-like symptoms using a twosided two-sample t-test with the significance level at a ¼ 0.05.
Gene ontology (GO) analysis
We examined the set of IFN-b-responsive genes for overrepresented GO terms to assess their functional characteristics. Using GOstats, a software package written in R, 28 each GO term was tested whether it is significantly associated to the list of filtered genes, that is, whether it is related with higher frequency to these genes than to the 15734 genes measured in total. The analysis was performed for all gene functional annotations of the biological process GO category provided by the Bioconductor annotation package org.Hs.eg.db version 2.2.6 (http://www.bioconductor.org).
TFBS analysis
To reconstruct the regulatory interactions between the genes with expression changes in response to IFN-b, we applied a GRN inference algorithm that integrates information on TFBS as previous knowledge. Evolutionarily conserved TFBS were derived from the tfbsConsSites track of the UCSC database build hg18 (http://genome.ucsc.edu). The track data were generated using position weight matrices of TFBS contained in the public Transfac database (version 7.0, http:// www.gene-regulation.com/cgi-bin/pub/databases/transfac/). For the whole human genome 3837187 TFBS predictions associated to 258 different position weight matrices can be retrieved from the tfbsConsSites track (as of 19 November 2009) . With this at hand, we screened the regulatory region of each of the 15734 measured genes for TFBS occurrences. The regulatory region was specified as the genomic sequence 1000 bp up-and downstream of the transcription start site stated in the GeneCards database version 2.39 (http:// www.genecards.org). Furthermore, to take into account the inherent redundancy of the Transfac database, we grouped very similar or identical sequence motifs by use of STAMP. 29 In this way, we could reduce the 258 Transfac position weight matrices to 101 distinct DNA-binding patterns. Using a hypergeometric test, we identified a subset of (consolidated) TFBS motifs overrepresented at the significance level a ¼ 0.1. That means, these motifs are enriched in the regulatory regions of the filtered genes when compared with the distribution of TFBS within the promoter sequences of all measured genes. This information corresponds to a list of predicted TF-gene interactions that can serve as a template for inferring the GRN. A TF-gene interaction represents a physical interaction, that is, a TF (or a group of TFs with similar binding specificity) binds at least once the DNA at the region that encompasses the transcription start site of a gene and thus presumably regulates its transcription.
Integrative GRN modeling
We applied the TFBS-integrating least angle regression (TILAR) algorithm to construct a GRN model of IFN-b-responsive genes. TILAR is a novel method for inferring GRNs from gene expression data, incorporating known or predicted TFBS and, if available, literature mining information (adaptive TILAR). 26 The modeling approach distinguishes two types of network nodes: genes (that were selected for identifying the regulatory interactions between them) and TFs (whose binding sites are overrepresented in the regulatory regions of the genes). The algorithm then assigns (directed) TF-gene and gene-TF interactions (network edges) by fitting a system of linear equations to the genes' expression levels. In comparison with TF-gene interactions, gene-TF interactions can have different meanings, for example, the gene itself might encode a transcriptional regulator of the TF, or the gene product controls (possibly through a signaling cascade) the activity of the TF at the proteome level. Using both types of interactions, the modeling considers that genes usually regulate other genes indirectly through the activity of one or more TFs.
The actual GRN inference problem is formulated as a linear regression equation that satisfies specific constraints on the network structure: The model is constrained to be sparse reflecting that genes are regulated by a limited number of regulators. Moreover, TILAR includes only a subset of the putative TF-gene interactions obtained from TFBS analysis. As TILAR not necessarily employs all those TF-gene interactions, the method considers the fact that they are predicted and therefore not all of them might refer to biologically functional binding sites. The regression coefficients (that is, the nominal parameters in the model) to be estimated by least angle regression 30 then specify the presence and strength (edge weights) of each possible gene-TF interaction. The final model was determined by 10-fold cross-validation (to avoid overfitting to the data), visualized with Cytoscape 2.6.0, 31 and tested for scale-freeness according to Clauset et al. 32 For a more complete description of the modeling approach, we refer to our original paper on TILAR. 26 The major advantage of this inference technique is that only few model parameters are sufficient to define a complex network, which is still readily interpretable in terms of true molecular interactions. Moreover, TF expression levels are not required for the network reconstruction, as the activity of TFs is modeled implicitly. This is beneficial, as TF expression seldom correlates with TF activity. We evaluated and compared the performance of TILAR (including the adaptive variant) and five different GRN inference methods using literature mining information. A detailed report on this benchmarking analysis can be found in Supplementary Materials and Methods. We supply R codes for TILAR at our institute's website (http://www.hki-jena.de/ index.php/0/2/490).
Results
Patient characteristics
The demographic and clinical characteristics of the 24 patients in our study are summarized in Table 2 . A total of 20 patients had systemic side effects in form of flu-like symptoms (including fever, asthenia, myalgia and headaches) within the first 3 months on treatment. Two patients experienced a relapse in this observation period. None showed injection-site reactions or liver function abnormalities.
Transcriptional changes in response to IFN-b therapy
The preprocessing of the microarray data resulted in an expression data set of 15734 different genes and 72 PBMC samples. By filtering for genes significantly up-or downregulated after IFN-b-1a i.m. therapy onset, we detected gene expression changes that were common among the patients. We identified 102 genes as differentially expressed at week 1 versus baseline (Figure 1) , and 24 genes at week 4 versus baseline. Altogether, 72 genes were found upregulated and 49 genes downregulated, comprising a set of 121 filtered genes in total (Supplementary Table 1) . None of our patients showed an apparent spontaneously increased type I interferon activity before treatment, which is a phenomenon observed in a subgroup of untreated patients in other studies. 17, 18 The permutation test disclosed that the number of 121 differentially expressed genes is significantly higher than would be expected by chance. When randomly shuffling the sampling time points for each patient for 1000 times and analyzing each permutated data set for modulated genes, between 8 and 89 genes were filtered (on average 21.4). Hence, the number of filtered genes was below 121 in each permutation, which implies an empirical P-value for the actual filtering result of o0.001. This shows that (most of) the identified messenger (m)RNA changes are due to the therapy.
The overall patterns of gene expression revealed by realtime PCR were similar to those obtained using microarrays. The mRNA measurements of both techniques correlated significantly for all 15 remeasured genes. When comparing the expression levels before first and second IFN-b injection, real-time PCR analysis also confirmed the significance of expression changes for all of these genes. Full results of the real-time PCR experiments are presented in Supplementary Materials and Methods.
Functional analysis of IFN-b-responsive genes
The result of the GO analysis (Table 3 , Supplementary Table 1) shows that most of the filtered genes are known to participate in immune system processes. Genes associated to 'positive regulation of immune response' are significantly enriched in the gene set. The corresponding GO category (GO:0050896) comprises 26 out of the 121 genes, including TNFSF10, TLR7, FCER1A, IL1R2, OAS1 and AQP9. These genes have quite diverse immune functions. OAS1, a member of the 2-5A synthetase family, is an essential IFN-inducible protein involved in the innate immune response to viral infection. 33 The water-selective membrane channel AQP9 is thought to have a role in the immunological function of leukocytes. 34 FCER1A is an Fc receptor for IgE molecules, which after crosslinking can lead to induced NF-kB activation in monocytes and thus cytokine production. 35 Apart from that, 10 of the genes in the category 'positive regulation of immune response' constitute a subgroup of genes annotated with the GO term 'B cellmediated immunity' (GO:0042221).
G proteins (GNAZ and GNG8) and G protein-coupled receptors (GPR20, GPR44, GPR56 and GPR97) also showed significant expression changes in response to the therapy. Modifications in the activity of GPRs characterize lymphocytes from MS and other chronic immune disorders, and it is assumed that IFN-b-1a affects the expression of GPR regulatory proteins. 36 Besides, we noted an upregulation of specific cell adhesion molecules (AM) including the integrins (JAM3, ESAM, CLDN5, ITGA2B and ITGB3). Within the immune system, AM mediate cell contacts and bring leukocytes to sites of inflammation or injury, and thus they may be important in MS brain lesions 4 (see Discussion).
Comparison with other expression profiling studies on IFN-b-1a i.m. Several of the 121 filtered genes have already been described as genes altered at the transcript level in response to i.m. IFN-b-1a therapy. In the study by Fernald et al., 20 immune Signal intensities were centered and scaled row-wise (yielding z-scores) for visualization purposes. Despite a strong interindividual variability, the clustering tends to separate baseline measurements (green labeled columns) from gene expression levels obtained at 1 week into therapy (gray). The data of only few patients do not cluster according to the time points, for example, for patient 16 (the two leftmost columns), who already showed at baseline a relatively high expression of some genes generally found upregulated after 1-week therapy. The row labels of the heatmap, that is, the gene symbols, are given in Supplementary  Table 1 . Exemplary, the dynamics of five down-and two upregulated genes are shown on the right. The y-axis is the average expression level of the 24 patients, and error bars indicate standard errors. *P-valueo0.005, þ P-valueo0.05.
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system process (GO:0002376) genes OAS1, CST7, SNCA and CSF1R were found modulated by the treatment, too. Their study focused on the fast blood expression changes within two days after drug administration. CSF1R, which was downregulated after 1 and 4 weeks into therapy in our study, is a receptor for colony stimulating factor-1, a cytokine that controls differentiation and function of monocytes and macrophages. 37 The downregulation of CSF1R was confirmed by real-time PCR analysis (Supplementary Materials and Methods). In another study, Singh et al. examined five MS patients before and 24 h after initial therapeutic dose of IFN-b-1a i.m. and identified a set of 132 differentially expressed genes. 19 At least eight of these genes also occur in our filtering result: TNFSF10, OAS1, JUP, AQP9, FGFBP2, MS4A4A, TYMP and FAM26F. The mRNA levels of TNFSF10 are known to be increased in PBMC from MS patients compared with healthy controls 38 and even have been reported to be predictive of clinical responsiveness to IFN-b. 39 TNFSF10 encodes a cytokine of the tumor necrosis factor ligand family that induces apoptosis and activation of NF-kB. Regulation of TNFSF10 function takes place at the level of receptor expression, whereas decoy receptors such as TNFRSF10C can inhibit TNFSF10 from binding to tumor necrosis factor receptors capable of mediating apoptosis. 40 We found TNFRSF10C significantly upregulated after first injection of IFN-b-1a i.m., but the expression returned to baseline levels at the 4 weeks time point.
Identification of putative TF-gene interactions
Genes responsive to IFN-b-1a are under control of TFs, whose activities are (indirectly) affected by the drug. Therefore, we analyzed the genes' regulatory regions for occurrence of overrepresented TFBS. Conserved binding sites were found enriched for 11 consolidated TFs, which indicates that the genes share common regulatory regimes. These 11 TFs connect 77 out of the 121 genes through 152 TF-gene interactions, and each TF is linked to at least eight genes (Table 4) . This information was used as a template for inferring the underlying GRN by TILAR. As a reminder, each TF-gene interaction is only a potential one, as this analysis was based on computationally predicted TFBS because of the lack of experimentally determined TFBS in biological databases.
It is also important to note that some TFs with highly similar DNA-binding properties were grouped to one TF entity, for example, the interferon regulatory factors (IRF)-1 and 2. IRF1 and IRF2 are structurally similar and bind to the same regulatory elements. However, they have distinct or even antagonistic functions. IRF2 is a repressor that competitively inhibits the IRF1-mediated transcriptional activation of interferons and IFN-inducible genes. 41 A subset of 21 genes possess at least one TFBS for NF-kB (NFKB1, NFKB2, REL, RELA). NF-kB proteins are key regulators in the transcription of many inflammatory genes and are activated by various intra-and extracellular stimuli, for example, cytokines like IFN-b. They can be found in numerous cell types that express cytokines, cell AM and acute phase proteins.
Integrative network modeling
On the basis of the gene expression data (121 genes, 72 samples) and the predicted TF-gene interactions, we constructed a GRN model using the TILAR algorithm. The modeling was constrained to use only a subset of the putative TF-gene interactions. Here, 102 out of the 152 predicted TF-gene interactions were included into the model. Overall, 28 nominal model parameters were set nonzero specifying the presence of gene-TF interactions. Network inference by TILAR outperformed all other algorithms tested in the benchmarking analysis described in more detail in Supplementary Materials and Methods. TILAR allowed for a higher prediction accuracy than using just gene expression data or TFBS information alone, and performed best when incorporating text-mining information as well (adaptive TILAR). Therefore, we confirmed that the integrative modeling strategy is able to reconstruct GRNs more reliably than other established methods.
Network characteristics
The inferred network is fairly complex but still readily interpretable because of the intuitive linear modeling scheme. Each network node is under control of only few regulators rendering the network sparse. The maximum indegree in the GRN is five (on average 1.57). Nevertheless, some nodes (in particular TFs) are highly connected in the network, for example, the NF-kB complex with an outdegree of 15 ( Figure 3b) . Overall, most of the nodes are lowly connected and only a few are relatively highly connected. The node degrees are roughly distributed according to a power law (scale-free topology), with the fraction P(k) of nodes in the network having k connections being estimated to follow P(k)Bk À2. 16 .
A closer look at the interactions in the model revealed gene sets co-regulated by a common TF (Figure 3a) . In the network, nine genes are under transcriptional control of Abbreviation: TF, transcription factor. Evolutionarily conserved TFBS of 11 TF entities were found enriched. The list includes IRFs and NF-kB, which are known TFs in IFN-b signaling. 8 Highly similar Transfac motifs were consolidated before calculating the P-values. The column 'Count' shows the number of genes that possess a DNA-binding site for the respective TF. For instance, 9 out of the 121 genes have a potential TFBS for IRF1/IRF2 in their promoter region, which is significantly more than expected by chance ('Expected Count' is 5.33). In sum, there are 152 predicted TF-gene interactions. TFCP2, of which all but one was upregulated after first week of IFN-b-1a i.m. administration (for example, ALOX12, GPR97 and CMTM5). Similarly, TF node ZIC1|ZIC2|ZIC3, which represents a group of ZIC family zinc finger proteins, is linked to seven genes. Of these, six genes showed lowered mRNA levels in the patients' PBMC 1 week post therapy initiation in comparison with baseline (for example, JUP, FAM26F and EGR2). The TFs ZIC1, ZIC2 and ZIC3 were grouped during TFBS analysis as they bind the same or at least very similar DNA sequences. 42 The GRN model contains four regulatory feedback loops and 25 feedforward loops of minimal length (that is, just four edges) as determined by an exhaustive search. An exemplary feedback loop in the reconstructed network is the regulatory chain 'NF-kB-EHD3-TFCP2-ALOX12-NF-kB' (Supplementary Materials and Methods, Cytoscape session file). EHD3 and ALOX12 were both found upregulated immediately before second IFN-b injection.
Patients with and without flu-like symptoms within the first 3 months of IFN-b therapy showed significant differences in the transcript levels of the IFN-b-responsive genes. There were six genes that not only displayed elevated amounts of mRNA after 1-week therapy with IFN-b-1a i.m., but that were also highly expressed before start of treatment in the group of patients with side effects (Figure 4 , Supplementary Table 1) . Interestingly, five of these genes and two TFs (NF-kB, TOPORS) form a regulatory subnetwork (Figure 3b ). DNA-binding sites for NF-kB were found in the regulatory region of three of these genes. Our GRN inference result thus suggests that NF-kB regulates genes associated with adverse effects of IFN-b therapy.
It should further be noted that four out of the five genes in the sub-network (all but ANKRD9) showed at least a trend (t-test P-valueo0.10) for higher expression in patients with flu-like symptoms not only at baseline, but also at week 1 and 4. That means, the differences in basal expression maintained, even when the genes were generally upregulated 1 week after drug injection in both patient groups. Figure 2 . (a) Network inference by TILAR takes into account that TF target genes are often co-expressed. All but one of the genes that are regulated by TFCP2 is upregulated after therapy initiation. Similarly, a set of downregulated genes is predicted to contain DNA-binding sites for ZIC family members in their regulatory regions. Both TFs receive multiple regulatory inputs. (b) Some of the filtered genes have potential relevance to treatment-related adverse effects. The figure on the right shows a sub-network of genes that are highly expressed at baseline in patients experiencing side effects. According to the model, three of these genes are regulated by NF-kB, a main transcriptional regulator in the network. Outer parts are shown with lower opacity. Figure 4 Expression differences between patients with and without side effects. Of the 121 filtered genes, six genes were found to be significantly highly expressed (t-test P-valueo0.05) before treatment in patients suffering from flu-like symptoms early in therapy. Bars indicate mean and standard error.
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We analyzed transcriptional changes in response to 30 mg once-weekly, i.m. IFN-b-1a treatment in blood cells of MS patients. For this purpose, PBMC were isolated, which comprise mainly lymphocytes (that is, B, T and NK cells) and monocytes, but also some thrombocytes that remain after Ficoll separation. A set of 121 genes was found significantly altered in the PBMC during the first 4 weeks of drug administration. In this set, GO analysis revealed an overrepresentation of immunologically relevant genes ( Table 3 ). The impact of IFN-b therapy on gene expression was greater after 1 week of therapy than after 1 month. This is compatible with results of similar studies 11, 19 and possibly suggests a homeostatic response to the drug by mechanisms that counter-regulate some changes in expression. From a statistical perspective, however, the longer-term therapeutic effects may also be diluted by variations in the patients' life style, nutrition, co-medication and so on. On the basis of the expression data, we further determined the putative TFs mediating the gene regulatory effects of IFN-b and constructed a GRN model. Subsequent network analysis identified 'network motifs', that is, frequent interaction patterns such as feedback and feedforward loops. A sub-network of genes was found more active in patients reporting flu-like symptoms, demonstrating that the inferred network could reflect clinical heterogeneity.
Studies on pharmacogenomic effects of IFN-b in PBMC often differ in their experimental design: Gene expression changes have been investigated in response to different IFNb treatment regimes (IFN-b-1a i.m. and s.c., as well as IFN-b1b s.c.), sometimes pooling patients receiving any of these therapies. 15 We examined a relatively large homogeneous cohort of relapsing-remitting MS patients (n ¼ 24, expanded disability status scale baseline range 0-2.5) who all were treated with IFN-b-1a i.m. at standard dose so that the findings are not distorted by differences in form, dose and route of drug administration. Apart from that, the observation period explored by other groups ranges from a few hours until years into therapy (see also Table 1 ). The dynamics during the first hours have been studied particularly intensively. It was shown that changes in expression can be seen within 2-4 h after drug administration. [9] [10] [11] [12] Among the early IFN-b-induced genes are MX1, B2M, TNFSF10 and OAS1. Their mRNA and protein levels decline to baseline between 96 and 144 h after IFN-b administration. [10] [11] [12] 43, 44 Hence, once-a-week dosing of IFN-b-1a i.m. does not maintain these genes above baseline throughout a week. In our study, blood samples were drawn from the patients immediately before first, second and fifth i.m. injection of IFN-b-1a. The data revealed the genes that are affected by the therapy even 1 week after last injectionpresumably indirectly as a consequence of the activity of early IFN-induced genes-and therefore unveil the more persistent and late changes to the transcriptome. Some of the 121 filtered genes have been mentioned in related studies on other IFN-b treatment regimes. For instance, the general immune response regulators (GO:0050896) OAS1, JUP and TNFSF10 have been described as upregulated in PBMC of MS patients receiving IFN-b-1b s.c. for at least 6 months. 45 These three genes were lower expressed at 1 week versus baseline in our data, which might be explained by the weekly drug injection and blood sampling: As mentioned above, these genes are known to be upregulated after a few hours, but their expression returns to pre-treatment values after a few days. 10, 44 Possibly, mechanisms that actively counter-regulate the transiently increased expression of OAS1 and other early IFN-induced genes might even lead to week-1 mRNA levels that are reduced compared with baseline. Besides, we observed an elevated expression of ESAM in agreement with the results of Annibali et al. 46 In comparison with our study they used microarrays to obtain long-term expression profiles of PBMC from 7 MS patients receiving IFN-b-1a subcutaneously. We recently published a pharmacogenomic study where we applied Affymetrix microarrays to measure the PBMC expression levels of 25 patients treated with IFN-b-1b s.c. 47 In this data set, FCER1A was the only gene consistently downregulated over the whole observation period of 2 years. FCER1A was also found significantly decreased after start of IFN-b-1a i.m. therapy in the present work. Its downregulation was confirmed by real-time PCR experiments in both studies. We thus conclude that FCER1A is generally repressed by IFN-b treatment.
According to our data, IFN-b therapy induces the expression of AM. Changes in the composition of AM in the peripheral blood of MS patients receiving IFN-b have already been discussed in the literature. 48, 49 We found significantly increased levels of the two integrins ITGA2B and ITGB3 at 1 week into therapy. They are known to form a complex (glycoprotein IIb/IIIa), which mediates aggregation of activated platelets by acting as an integral membrane receptor for fibrinogen and other ligands. 50 Hence, this complex has a crucial role in coagulation by plugging the endothelial layer of damaged blood vessels. Elevated amounts of glycoprotein IIb/IIIa potentially have beneficial effects in MS, where the blood-brain barrier is disrupted. Upregulated ESAM encodes a cell-surface protein that also localizes to the junctions between adjacent platelets and is thought to limit the stability of platelet contacts so that the optimal hemostatic response occurs following vascular injury. 51 ESAM further mediates homophilic adhesion of other expressing cells, has been linked to integrity and formation of blood vessels, 52 and is under control of NF-kB in the inferred GRN. ESAM is related to junctional adhesion molecule (JAM) family members, of which JAM3 was also found to be highly expressed at week 1 versus baseline. JAM3 is produced by and regulates adhesion between leukocytes, platelets and endothelial cells, and is involved in the migration of leukocytes across the endothelium during inflammation. 53 However, it is difficult to specify the true effect or cause of JAM upregulation after IFN-b injection as for example, we cannot break down the measured expression levels to a certain cell type: one possibility is that JAM3 is primarily upregulated in platelets, where it can function as a counter-receptor for the leukocyte integrin Transcriptional effects of IFN-b therapy in MS Mac-1. 53 This way, it could inhibit Mac-1-dependent adherence of neutrophils and monocytes and their transendothelial migration at the blood-brain barrier in MS patients. A second possible mechanism might be that the treatment stabilizes the blood-brain barrier and thus stops a gradual loss of immune cells which migrate from the blood into the central nervous system. 48 Activated PBMC that stay in the blood then could lead to a relative increase in the expression of AM including JAM3. However, many open questions remain on whether and how these transcriptional changes of AM exactly contribute to therapeutic effects.
Evidently, the broad effects of IFN-b are not purely antiinflammatory and beneficial. IFN-b treatment in relapsingremitting MS can frequently induce systemic side effects such as flu-like symptoms with fever. In contrast to changes in magnetic resonance imaging and relapse rate, a number of adverse effects emerge at the early phase after therapy initiation. They can lessen over time, but a considerable amount of patients suffers from persistent or recurring side effects which may cause them to cease the treatment. 23 To improve the clinical success of therapy an individualized tolerability management may be supported by molecular markers, but studies in this field are rare. Montalban et al. 54 supposed that patients who develop fever during IFN-b therapy generally have increased levels of interleukin-6. In our study, some IFN-b upregulated genes were found to be significantly highly expressed at baseline in the group of MS patients with flu-like symptoms in the first 3 months of medication (ESAM, ALOX12, ELOVL7, ANKRD9, GNAZ, SLC24A3). The aforementioned ESAM promotes intercellular adhesion, but it was also speculated that increased levels of such AM as markers of immune activation might be associated with the side effects of IFN-b treatment, in particular flu-like symptoms. 48 The lipoxygenase enzyme ALOX12 is present in leukocytes and thrombocytes, and synthesizes leukotrienes (12(S)-HETE). 55, 56 Leukotrienes are bioactive lipids that have been implicated in allergic and inflammatory reactions. They are potent effectors of hypersensitivity responses and can cause (flu-like) symptoms such as bronchoconstriction and increased secretion of mucus. 57 Specific studies on 12(S)-HETE further revealed multiple functions, for example, modulation of integrin expression 56 and stimulation of angiogenesis. 55 Besides, the observed upregulation of ALOX12 in response to IFN-b is remarkable as in the animal model of MS ALOX5-and ALOX15 deficiency both confer a significantly worse disease course. 58 For the other differentially expressed genes, it should only be mentioned that, like ALOX12, ANKRD9 and ELOVL7 are also thought to be involved in lipid metabolism. 59, 60 Interestingly, NF-kB occurs as a regulator of a subset of these genes in the reconstructed GRN and its activity therefore potentially correlates with treatmentrelated flu-like symptoms as well (Figure 3b) . Apart from that, HNF1A is connected to seven genes in the network. This TF is required for the expression of several liver-specific genes, and we hypothesize that its involvement coincides with liver function abnormalities common in patients who are treated with IFN-b. 61 However, the true significance and clinical relevance of the detected differential gene expression in patients with and without side effects and the potential roles of NF-kB and HNF1A remain to be further examined.
To better understand the pharmacologic effects of IFN-b in MS, it is crucial to unravel the regulatory interaction structure of genes responsive to the immunotherapy. According to the GRN inferred by TILAR, IFN-b mediates immune regulation through diverse TFs including some so far unrecognized in MS research. The inferred network reflects many fundamental properties that constitute a GRN including sparseness, scale-freeness, decentralization, self-regulation (feedback) and co-regulation. Moreover, the model reveals network regions, for instance genes downregulated by ZIC family members and a highly interconnected NF-kB (Figure 3) , and thus provides testable hypotheses about the drug's mechanisms of action.
To date, our knowledge on the biological processes underlying MS and the efficacy and safety of available medications is still limited. Individualized treatment and monitoring strategies are necessary to use them in a more cost-effective way. An improved pharmacodynamic, maybe even cell type-specific understanding at the transcript level should help to assess and individually optimize MS treatments with IFN-b. Once established, this would protect the patients against unnecessary drug exposure and side effects. Several IFN-b-responsive genes with potential prognostic value have already been discussed in the literature, 39, 45, 62 and we intend to scrutinize the use of such predictors on our data once we have long-term clinical information for our patients. In this study, we described sustained PBMC gene expression changes during first month of IFN-b-1a i.m. administration and derived the regulating TFs. We identified a network region of genes associated to therapeutic side effects and linked to NF-kB activity. A potential regulatory feedback loop with NF-kB has been found. FCER1A, which is known to induce NF-kB activation, 35 was affirmed as one of few genes significantly repressed by IFN-b. To conclude, we showed that network analysis integrating different types of biological data could provide new insights into treatmentaffected processes, and expose expression differences between the patients of possible clinical relevance.
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